Comparison of Survival Prognostic Tools in Terminal‐Stage Tumor Patients: A Multicenter Prospective Cohort Study
Cancer Medicine · 2026
DOI: 10.1002/cam4.72283 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, 2026. Verfasst von Ziluo Cheng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Thoracic Surgery Unit, Jiangsu Cancer Hospital, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Neoplasms, Terminal Care. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aim
Previous studies have discussed the effectiveness of the Karnofsky Performance Scale (KPS), Palliative Performance Scale (PPS), Palliative Prognostic Index (PPI), and Delirium‐Palliative Prognostic Score (D‐PaP) in predicting the survival of patients with terminal‐stage tumors, but their effectiveness in the Chinese terminal‐stage tumor population still needs to be explored. Therefore, we conducted this prospective cohort study to investigate the applicability of KPS, PPS, PPI, and D‐PaP in predicting survival in Chinese patients with terminal‐stage tumors.
Methods
This is a prospective cohort study that collected data from 449 terminal‐stage tumor patients across four medical institutions in China from January to December 2024. The feasibility of using KPS, PPS, PPI, and D‐PaP to predict the 7‐day and 30‐day survival of terminal‐stage tumor patients was discussed through ROC curves. Kaplan–Meier survival curves were used to examine the survival differences of terminal‐stage tumor patients using four survival prediction tools with new cut‐off values.
Results
The study ultimately included 449 patients with terminal‐stage tumors. For the prediction of 30‐day survival, the area under the ROC curve of KPS, PPI, PPS, and D‐PaP was 0.842, 0.749, 0.778, and 0.898, respectively. In our study cohort, the optimal cut‐off values were 25, 3, 35, and 9.25. Their corresponding sensitivity was 86.3%, 92.3%, 77.7%, and 76.0%, while their specificity was 69.7%, 44.4%, 67.7%, and 93.9%, respectively.
Conclusion
The results of this multicenter cohort analysis reveal that in terminal‐stage tumor patients in China, KPS, PPS, PPI, and D‐PaP are all effective for predicting survival. Specifically, D‐PaP is more applicable for predicting 30‐day survival. Although D‐PaP showed the most significant predictive power, its accuracy in predicting 7‐day and 30‐day survival outcomes was not significantly superior to that of experienced palliative care professionals. Therefore, future research still needs to develop or update scoring tools with better predictive performance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Thoracic Surgery Unit, Jiangsu Cancer Hospital, Nanjing, Jiangsu, China.
- Head and Neck Surgery Unit, Jiangsu Cancer Hospital, Nanjing, Jiangsu, China.
- Intensive Care Unit, Jiangsu Cancer Hospital, Nanjing, Jiangsu, China.
- Department of Pain Management, Jiangsu Cancer Hospital, Nanjing, Jiangsu, China.
ORCID-Profile: Ziluo Cheng
Zitieren
APA
Cheng, Z., Jin, L., Mei, Z., & Wang, Y. (2026). Comparison of Survival Prognostic Tools in Terminal‐Stage Tumor Patients: A Multicenter Prospective Cohort Study. Cancer Medicine. https://doi.org/10.1002/cam4.72283
Vancouver
Cheng Z, Jin L, Mei Z, Wang Y. Comparison of Survival Prognostic Tools in Terminal‐Stage Tumor Patients: A Multicenter Prospective Cohort Study. Cancer Medicine. 2026. doi:10.1002/cam4.72283
BibTeX
@article{Cheng2026,
author = {Cheng, Ziluo and Jin, Lu and Mei, Zhen and Wang, Yeping},
title = {Comparison of Survival Prognostic Tools in Terminal‐Stage Tumor Patients: A Multicenter Prospective Cohort Study},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.72283}
}
EUVIMED